Alumis vs ConcertAI
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alumis is a clinical-stage biopharmaceutical company developing oral TYK2 inhibitors for immune-mediated diseases including psoriasis, lupus, and inflammatory bowel disease; raised over $400M in private funding;
About
Alumis is a South San Francisco-based clinical-stage biopharmaceutical company founded in 2021 by Martin Babler and Joseph Arol, with a focus on developing precision oral therapies for patients with serious immune-mediated diseases. The company's lead program, ESK-001, is a highly selective TYK2 (tyrosine kinase 2) inhibitor targeting conditions including moderate-to-severe plaque psoriasis, systemic lupus erythematosus (SLE), and inflammatory bowel disease. TYK2 inhibition is a validated immunology mechanism — Bristol Myers Squibb's Sotyktu (deucravacitinib) was the first approved TYK2 inhibitor — and Alumis is developing what it believes is a next-generation molecule with improved selectivity.
ConcertAI is an oncology AI and real-world data company at a $1.9B valuation — 5.5M multi-modal cancer RWD records, $230M+ raised, exiting FY2024 profitable with mid-teens EBITDA margins.
About
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates multi-modal patient data — including electronic health records, genomics, imaging, and pathology — from a network of oncology providers to support biopharma companies in clinical trial design, site selection, protocol optimization, patient matching, and regulatory submission.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.